B

In the pre-specified analysis of the ZEUS trial, high-bleeding-risk patients who received a zotarolimus-eluting stent had significantly better ischemic outcomes and no increase in bleeding compared with those who received a bare-metal stent. The authors concluded that drug-eluting stent implantation “provides superior efficacy and safety as compared with conventional BMS,” indicating that bare-metal stent use is no longer justified in this population [Ariotti et al., 2016, PMID 26965932].